UroGen Pharma Ltd. · TRADEGATE:UR8

UroGen Pharma Ltd. financial statements

UroGen Pharma Ltd.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue109.8M90.4M82.7M64.4M48.0M11.8M18.0K1.13M8.16M17.5M
Cost of revenue12.4M8.88M9.36M7.65M5.16M1.01M48.0K1.80M600.0K28.0K
Gross profit97.3M81.5M73.4M56.7M42.9M10.8M18.0K-675.0K7.56M17.5M
Research and development67.1M57.1M45.6M52.9M47.6M47.3M49.3M36.9M18.7M10.3M
Selling, general and administrative155.1M121.2M93.3M82.8M87.5M90.2M60.2M39.6M8.81M6.42M
Operating income-124.9M-96.8M-65.5M-79.0M-92.3M-126.7M-109.5M-77.2M-19.9M798.0K
Depreciation and amortization307.0K329.0K802.0K924.0K831.0K416.0K300.0K400.0K200.0K200.0K
EBITDA-124.6M-96.5M-64.7M-78.1M-91.5M-126.3M-109.2M-76.8M-19.8M998.0K
Interest expense33.8M12.5M14.7M8.44M17.4M3.67M284.0K000
Income before tax-153.4M-124.0M-98.3M-108.0M-109.4M-125.1M-105.1M-75.5M-20.0M-1.94M
Income tax78.0K2.83M3.92M1.75M1.45M3.37M-4.62M125.0K19.0K0
Net income-153.5M-126.9M-102.2M-109.8M-110.8M-128.5M-105.1M-75.7M-20.0M-1.94M
Earnings per share, basic-3.19-2.96-3.55-4.81-4.96-5.90-5.12-4.80-2.14-1.91
Earnings per share, diluted-4.96-5.90-5.12-4.80-2.14-1.91

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents110.7M172.0M95.0M55.4M44.4M52.9M49.7M101.3M37.0M21.4M
Short-term investments49.3M110.7M56.2M44.6M44.8M49.2M97.4M36.0M95.0K
Receivables33.1M20.3M15.4M12.7M11.7M7.05M198.0K83.0K
Inventory16.5M9.23M5.67M4.33M4.83M1.96M316.0K105.0K
Current assets186.0M276.1M169.2M128.9M114.4M115.6M148.6M102.2M74.5M22.0M
Property, plant and equipment637.0K655.0K689.0K1.30M1.97M2.05M977.0K948.0K805.0K741.0K
Total assets200.5M285.7M178.3M135.6M119.7M122.0M202.4M103.6M75.5M23.1M
Accounts payable12.1M10.9M6.51M5.53M5.79M3.27M4.69M4.27M2.84M1.88M
Current liabilities46.4M45.9M31.2M23.9M22.4M21.4M19.5M13.5M7.04M3.14M
Long-term debt122.2M121.7M98.6M97.5M03.61M
Total debt125.0M121.7M98.6M97.5M01.50M2.60M
Total liabilities305.9M294.5M243.5M225.0M111.3M25.6M22.1M13.5M7.04M6.75M
Shareholders' equity-105.5M-8.80M-65.2M-89.4M8.41M96.4M180.3M90.1M68.5M16.3M
Shares outstanding48.4M42.2M32.5M23.1M22.5M22.2M21.0M16.2M13.8M2.31M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-162.4M-96.8M-76.4M-87.6M-84.9M-105.9M-71.0M-37.3M-9.57M4.19M
Capital spending-289.0K-295.0K-194.0K-254.0K-752.0K-1.22M-325.0K-560.0K-271.0K-695.0K
Free cash flow-162.7M-97.1M-76.6M-87.8M-85.6M-107.1M-71.3M-37.9M-9.84M3.49M
Cash from investing61.6M-20.6M-953.0K1.06M4.07M93.2M-145.6M35.3M-36.3M-719.0K
Cash from financing39.9M194.6M116.9M97.1M72.3M16.5M165.3M66.4M61.6M-9.00K
Share buybacks1.35M-83.0K16.5M165.3M66.6M61.6M570.0K
Change in cash-61.0M77.2M39.6M10.6M-8.50M3.88M-51.4M64.4M15.7M3.46M